Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company
developing first-in-class drug candidates targeting the innate immune system, today
announces an operating revenue of 12.9 million Euros for the year 2008. Turnover for the year
amounted to 7.5 million Euros, including 1.6 million Euros in the fourth quarter ended
December 31, 2008.
